COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01254708
Recruitment Status : Suspended (Study has been placed on hold due to unavailability of funding.)
First Posted : December 6, 2010
Last Update Posted : October 19, 2011
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:

Lung transplant recipients have the highest rate of Invasive Aspergillus (IA)infection among solid organ transplant recipients. The most important risk factor for the development of IA (which is associated with disease and death) is colonization of the organism in the respiratory tract.

Azoles are used to prevent the development of IA. Puffers containing antifungal medication can be used to treat the lungs without the need to worry about the medication interactions & side-effects in the blood. An example of this is the aerosolized amphotericin B. Its use is limited by the patients' tolerating this medication that may cause cough, nausea & contraction of the air pathways.

The lipid preparation is better tolerated and has longer dosing interval than inhaled amphotericin B. The investigators propose a pilot study to determine the long-term safety of inhaled AmBisome administration of drug and generate the preliminary data on the effectiveness of this drug to prevent aspergillus colonization.

Condition or disease Intervention/treatment Phase
Lung Transplant Recipient Drug: Ambisome ® Drug: Regular standard of care medication Phase 2

Detailed Description:

In this pilot study, our main aims are:

  1. To determine the safety of once weekly Inhaled AmBisome prophylaxis in preventing the development of Aspergillus colonization in lung transplant recipients at one year of prophylaxis.
  2. To generate the preliminary data on the efficacy of Inhaled AmBisome (Astellas) loading dose (1mg/kg/day for four days) initially followed by q weekly dosage to complete 1 year in lung transplant recipients as compared to no prophylaxis by assessing the rate of fungal colonization/infections between the groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Pilot Study to Determine the Safety and Clinical Efficacy of Once-Weekly Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients
Study Start Date : January 2012
Estimated Primary Completion Date : January 2014
Estimated Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Control
Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
Drug: Regular standard of care medication
Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole

Experimental: liposomal amphotericin B (AmBisome ®)
Inhaled Liposomal preparation of Amphotericin B.
Drug: Ambisome ®
liposomal amphotericin B

Primary Outcome Measures :
  1. Pulmonary Function [ Time Frame: Day 1 to 12 months ]
    Assess pulmonary function measurements i.e. changes in FEV1 (Forced Expiratory Volume 1), changes in FVC (Forced Vital Capacity) while receiving inhaled liposomal amphotericn B.

  2. Symptoms [ Time Frame: Day 1 to 12months ]
    Assess onset of symptoms including headache, dizziness and fatigue, fever, nausea, vomiting, wheezing, cough, shortness of breath, and taste preservation, while receiving inhaled liposomal amphotericin B

  3. Renal or Hepatic dysfunction and Neutropenia [ Time Frame: Day 1 to 12 months ]
    Assess the development of renal or hepatic dysfunction and neutropenia by measuring serum creatinine liver enzymes and white blood cells

Secondary Outcome Measures :
  1. Presence of Invasive fungal infection [ Time Frame: 1 year ]

    Measure the time in months from randomization of study participants to diagnosis of invasive fungal infection (proven or probable). Measure the time in months from randomization to death for study participants.

    Assessment of the quality of life at the baseline Month 0, 3, 6, 9 and 12 months based on responses to a questionnaire. These include responses to general questions to rate the level of emotions and the general well being of the study participants. These responses are rated as never, sometimes, often or always experienced.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Single or double lung transplant recipients who are at least one year out of transplantation.
  2. Age >18yrs of age
  3. Able to understand and complete informed consent.

Exclusion Criteria:

  1. Pregnant woman or woman capable of bearing children, who will not perform urine pregnancy test.
  2. Nursing mothers.
  3. Subjects with hypersensitivity to Amphotericin deoxycholate or liposomal Amphotericin.
  4. Subjects with a past history of bronchospasm associated with aerosol drug use.
  5. Subjects with active bacterial or viral infection as defined by the current use of non-prophylactic antibiotic anti-viral medications.
  6. Subjects treated with cytolytic medications (Campath /Thymoglobulin) within the last month.
  7. Subjects with an FEV1< 30% Predicted or FVC% <30%.
  8. Subjects requiring supplemental oxygen.
  9. Receipt of Inhaled or IV Amphotericin B within last 30 days.
  10. Subjects with known fungal infection as per MSG Criteria on therapy with antifungal drugs or diagnosed on the day of bronchoscopy.
  11. Current use of azoles active against molds (Voriconazole, itraconazole, posaconazole) for the prophylaxis.
  12. Serum creatinine > 150 mmol/L on the day of clinic visit.
  13. Liver enzymes ALT/ AST/ Alkphos greater than two times upper limit of normal.
  14. Concurrent intravenous aminoglycoside use.
  15. Subjects with fever > 38.2°C.
  16. Subjects on mechanical ventilation.
  17. Expected survival less than 6 months.
  18. Re-transplants and heart/lung transplant patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01254708

Layout table for location information
Canada, Ontario
University Health Network/ Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
University Health Network, Toronto
Layout table for investigator information
Principal Investigator: Shahid Husain, M.D M.Sc University Health Network, Toronto

Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT01254708    
Other Study ID Numbers: AGM201000428
First Posted: December 6, 2010    Key Record Dates
Last Update Posted: October 19, 2011
Last Verified: October 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Liposomal amphotericin B
Antifungal Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents